Related Experiment Video

Updated: Oct 7, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Genetics of arterial prothrombotic risk states

M S Williams1, P F Bray

  • 1Johns Hopkins University, Baltimore, Maryland 21205, USA.

Experimental Biology and Medicine (Maywood, N.J.)
|June 8, 2001
PubMed

Insights

Genetic factors influence arterial thrombosis, a key element in coronary artery disease. Understanding these inherited markers can improve patient management and personalize treatments for vascular disease.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Thrombosis Research

Background:

  • Coronary artery disease (CAD) is a major global cause of mortality.
  • Myocardial infarction (MI) involves complex pathophysiology, including atherosclerosis and thrombosis.
  • Genetic predisposition plays a significant role in the development of arterial thrombosis.

Purpose of the Study:

  • To review the genetic aspects of arterial thrombosis.
  • To identify key thrombotic factors associated with increased risk for CAD.
  • To explore the utility of genetic markers in managing vascular disease.

Main Methods:

  • Review of genetic epidemiology studies.
  • Analysis of in vitro laboratory data.
  • Examination of genetic components of coagulation, fibrinolysis, and platelet receptors.

Main Results:

  • Specific genetic variations in coagulation, fibrinolysis, and platelet receptors are linked to increased risk of acute coronary syndromes.
  • Genetic factors contribute significantly to the development of arterial thrombosis in CAD.
  • Inherited thrombotic markers offer potential for risk stratification.

Conclusions:

  • Genetic assessment of thrombotic factors can enhance traditional risk factor evaluation for CAD.
  • Personalized management strategies, including diagnostic testing and pharmacologic interventions, can be developed using genetic markers.
  • Future clinical practice may integrate genetic insights for more effective vascular disease management.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...